Engineered immune cells take on rare sarcomas in early trial
NCT ID NCT06083883
First seen Nov 01, 2025 · Last updated Apr 28, 2026 · Updated 31 times
Summary
This early-phase study tests a new treatment for people with advanced synovial sarcoma or myxoid/round cell liposarcoma. Participants receive donated immune cells (NK cells) that are engineered to recognize a protein called NY-ESO-1 on cancer cells, along with chemotherapy to prepare the body. The main goal is to find a safe dose and check for side effects. About 44 adults with specific genetic markers are being enrolled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYNOVIAL SARCOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.